Incyte Corp at TD Cowen Healthcare Conference Transcript
All right. Welcome back to the 46 Annual TD Cowen Healthcare Conference. Really happy to have the next session here with -- I'm Marc Frahm from the biotech team here at TD Cowen, and we're really happy to have the next session, Incyte with Bill Meury, the CEO, to join.
Questions & Answers
Maybe just start off with, Bill, do you want to -- just give a kind of high-level kind of staff up at the company? What do you think the kind of key value creation events for investors will be over the next 12 to 24 months?
Yes, sure. Thanks, Marc. I think about the business in three parts. Part one is we're focused on our core business ex Jakafi, which in 2025, finished at about $1.2 billion. We estimate by the end of '26, it could approach about $1.7 billion.
When we go out to 2030, we have a target for that business of $3 billion to $4 billion, which is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
